glp-1 gip therapies muscle preservation 2025 Q&A: Long-term success of hinges on more than just a prescription GLP-1 and GIP in Type

adults have used a GLP-1 drug, with about 6% currently using them (KFF Health Tracking Poll.) By 2030, the global GLP-1 market is projected to reach over $100 billion, underscoring the lasting impact of this trend

Q: What if I have health risks

The prospect that the 5-HT2A receptor mediates these effects warrants careful consideration

Frontiers in Endocrinology, 16 , 1754430

Emerging evidence was found assessing the GLP-1 RAs liraglutide, semaglutide, and tirzepatide and the effects on associated IIH symptoms (Table 3)

Long-Term Weight Loss & Maintenance with Semaglutide in Obesity (2022 Review of STEP Trials) consolidates findings across multiple STEP trials (1, 3, 4, 8), showing 14.917.4% mean weight loss over 68 weeks, improved cardiometabolic markers, and better quality-of-life outcomes